TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25465711

Group type: EXPERIMENTAL
Intervention: Group A (1 ml methylprednisolone acetate)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group B (1 ml methylprednisolone acetate + 15-day delayed 2 ml saline 0.9 %)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group C (1 ml methylprednisolone acetate + 15-day delayed 2 ml low molecular weight hyaluronic acid)
Number of subjects: 75
Study: 23635091

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 22076090

Group type: EXPERIMENTAL
Intervention: Unilateral plyometric training
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Bilateral plyometric training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 19726909

Group type: EXPERIMENTAL
Intervention: Home care nursing based palliative care program (experimental group)
Number of subjects: 46
Study: 17378196

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with point-injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study: 15126927

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 70
Study: 11346005

Group type: EXPERIMENTAL
Intervention: Standard CSU‐13B/P anti‐G suit (STD)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: STD suit with COMBAT EDGE (CE)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Advanced Technology Anti‐G Suit (ATAGS)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ATAGS with COMBAT EDGE (CE)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Seat-back angle effect
Number of subjects: 6

Group type: COMPARATOR
Intervention: Protective equipment effect
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ATAGS/CE with 13 and 30 degree seat-back angle
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ATAGS/CE with 55 degree seat-back angle
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ATAGS/CE with moderate straining at 55 degrees
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ATAGS/CE with additional straining at 13 and 30 degrees
Number of subjects: 6
Study: 9741373

Group type: EXPERIMENTAL
Intervention: Nose mask CPAP therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Face mask CPAP therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nose mask CPAP therapy for SAHS/U3P
Number of subjects: 30

Group type: COMPARATOR
Intervention: Face mask CPAP therapy for SAHS/U3P
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Long-term compliance for SAHS patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Long-term compliance for SAHS/U3P patients
Number of subjects: 30
Study: 7509355

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3127710

Group type: EXPERIMENTAL
Intervention: Withdrawal of carbamazepine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Withdrawal of phenytoin
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Withdrawal of sodium valproate
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Generalized seizures
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Complex or simple partial seizures without secondary generalized attacks
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Electroencephalographic class 4 (abnormal before treatment and unchanged before withdrawal)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Adults
Number of subjects: 92

Group type: COMPARATOR
Intervention: Children
Number of subjects: 92
Study: 321502

Group type: EXPERIMENTAL
Intervention: Albuterol aerosol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo aerosols
Number of subjects: 0
Study: 30406289

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) for urinary symptoms (nocturia, incontinence, frequency, dysuria, urgency)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) for gastrointestinal (GI) symptoms (obstruction, diarrhea, vomiting, nausea, bloating, hemorrhage, incontinence)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Physician-reported outcomes for urinary and GI symptoms
Number of subjects: 160
Study: 29029193

Group type: EXPERIMENTAL
Intervention: Intact FGF23 in girls
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: C-terminal FGF23 in boys and girls
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Iron concentration
Number of subjects: 721
Study: 25793219

Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: ProSeal LMA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 23419284

Group type: EXPERIMENTAL
Intervention: Vinflunine plus best supportive care (BSC)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Vinflunine plus BSC
Number of subjects: 370
Study: 22483428

Group type: EXPERIMENTAL
Intervention: Two-incision THA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Modified Watson-Jones THA
Number of subjects: 20
Study: 20437725

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Clearfil SE Bond)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium hydroxide liner (Dycal)
Number of subjects: 0
Study: 17972380

Group type: EXPERIMENTAL
Intervention: Beta-blockers (betaB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-renin system blockers (ARSB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACEI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARB)
Number of subjects: 0
Study: 16376756

Group type: EXPERIMENTAL
Intervention: Plasma triglyceride levels
Number of subjects: 424
Study: 11943522

Group type: EXPERIMENTAL
Intervention: Ketamine, propofol, and fentanyl
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sevoflurane, nitrous oxide, and fentanyl
Number of subjects: 76
Study: 9797520

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 40
Study: 8562538

Group type: EXPERIMENTAL
Intervention: 0.5% aldose reductase inhibitor (CT-112)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2762751

Group type: EXPERIMENTAL
Intervention: Standardized stress model
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-stressed conditions
Number of subjects: 19
Study: 327814

Group type: EXPERIMENTAL
Intervention: Fenoterol (prophylactic administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 31431411

Group type: EXPERIMENTAL
Intervention: IIV4-HD (high-dose quadrivalent influenza vaccine)
Number of subjects: 2670
Study: 28532660

Group type: EXPERIMENTAL
Intervention: micro-dose recombinant HCG
Number of subjects: 100

Group type: COMPARATOR
Intervention: recombinant LH
Number of subjects: 100
Study: 25294531

Group type: EXPERIMENTAL
Intervention: Cholecystectomy (n = 45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: GB left in situ (n = 45)
Number of subjects: 90
Study: 23866812

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment based (ACT+FB) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feedback group (FB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (FB and ACT+FB)
Number of subjects: 0
Study: 21270329

Group type: EXPERIMENTAL
Intervention: β-blockade using propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 19500095

Group type: EXPERIMENTAL
Intervention: Ultra-brief pulse bifrontal ECT at 1.5 times seizure threshold
Number of subjects: 64

Group type: COMPARATOR
Intervention: Unilateral ECT at 6 times seizure threshold
Number of subjects: 64
Study: 16860858

Group type: EXPERIMENTAL
Intervention: theory-based smoking cessation intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: general health counseling (control)
Number of subjects: 66
Study: 15327803

Group type: EXPERIMENTAL
Intervention: Exposure to strong pain expressions (number of prior exposures varied across four groups)
Number of subjects: 80
Study: 11132533

Group type: EXPERIMENTAL
Intervention: IFN alpha 6 MU tiw plus Ribavirin 14 mg/kg/day for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: IFN alpha 6 MU tiw
Number of subjects: 64
Study: 9309491

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and selegiline with physostigmine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8393474

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg)
Number of subjects: 101
Study: 3565811

Group type: EXPERIMENTAL
Intervention: Calcium chloride (2.5 mg/kg in children; 4, 8, 12 mg/kg in dogs)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Calcium gluconate (7.5 mg/kg in children; 14, 28, 42 mg/kg in dogs)
Number of subjects: 15
Study: 31017496

Group type: COMPARATOR
Intervention: Intralesional verapamil alone (2.5mg/ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of pulsed dye laser (PDL) and intralesional verapamil (2.5mg/ml)
Number of subjects: 40
Study: 30355464

Group type: EXPERIMENTAL
Intervention: Standard of care and radiotherapy (daily schedule: 55 Gy in 20 fractions over 4 weeks; weekly schedule: 36 Gy in six fractions over 6 weeks)
Number of subjects: 2061

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: Standard of care and radiotherapy
Number of subjects: 2061
Study: 27251682

Group type: EXPERIMENTAL
Intervention: FF/VI 50/25 µg, 100/25 µg or 200/25 µg, once daily
Number of subjects: 3255

Group type: COMPARATOR
Intervention: VI 25 µg, once daily
Number of subjects: 3255
Study: 24656240

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 1368

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1368
Study: 22856526

Group type: EXPERIMENTAL
Intervention: Shortened insemination method (4 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard insemination method (16-18 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rescue ICSI after failed fertilization with shortened insemination method
Number of subjects: 0
Study: 20482251

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 25
Study: 17850607

Group type: EXPERIMENTAL
Intervention: SRP plus adjunctive CHX chip placement
Number of subjects: 36

Group type: COMPARATOR
Intervention: SRP plus adjunctive systemic amoxicillin/metronidazole
Number of subjects: 36
Study: 16288433

Group type: EXPERIMENTAL
Intervention: Chronic renal failure group
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 19
Study: 11902611

Group type: EXPERIMENTAL
Intervention: Anti-adhesive enamel coating applied to buccal surfaces of teeth in one quadrant
Number of subjects: 39

Group type: COMPARATOR
Intervention: Untreated control quadrant
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Anti-adhesive enamel coating
Number of subjects: 39
Study: 10203382

Group type: EXPERIMENTAL
Intervention: Therapeutic regimens for MAC (specific regimens not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline quantitative mycobacterial load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Karnofsky score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous prophylaxis with rifabutin
Number of subjects: 0
Study: 7802306

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg immediately and droperidol 0.16 mg with each PCA dose (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg immediately (Group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Droperidol 0.16 mg with each PCA dose (Group 3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No droperidol (Group 4)
Number of subjects: 80
Study: 2148245

Group type: EXPERIMENTAL
Intervention: Large doses of MPA (Depo-Provera)
Number of subjects: 28
Study: 7053117

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25%
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125%
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% after interruption of local anaesthetic infusion
Number of subjects: 105
Study: 31931925

Group type: EXPERIMENTAL
Intervention: Intervention group (10 mmHg CO2 pressure)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Observation group (12 mmHg CO2 pressure)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Negative control group (14 mmHg CO2 pressure)
Number of subjects: 78
Study: 30206162

Group type: EXPERIMENTAL
Intervention: Ipatasertib combined with abiraterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28125821

Group type: EXPERIMENTAL
Intervention: MMC/5‐FU chemoradiotherapy
Number of subjects: 230

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: MMC/5‐FU vs. no chemotherapy (necrosis present)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: MMC/5‐FU vs. no chemotherapy (necrosis absent)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Presence vs. absence of necrosis
Number of subjects: 230
Study: 26378938

Group type: EXPERIMENTAL
Intervention: LNG-IUS 8
Number of subjects: 2884

Group type: EXPERIMENTAL
Intervention: LNG-IUS 13
Number of subjects: 2884

Group type: EXPERIMENTAL
Intervention: Both LNG-IUS 8 and LNG-IUS 13
Number of subjects: 2884
Study: 23685099

Group type: EXPERIMENTAL
Intervention: Automated intermittent bolus (5 mL every 30 min with 0.1 mL/hr basal rate)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Continuous infusion (10.1 mL/hr)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Automated intermittent bolus
Number of subjects: 45

Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 45
Study: 21509750

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy plus standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study: 19139445

Group type: EXPERIMENTAL
Intervention: Home fecal occult blood test (FOBT) kits offered during flu shot clinics
Number of subjects: 514

Group type: COMPARATOR
Intervention: Control group (flu shots only)
Number of subjects: 514
Study: 15865213

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 180 microg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2b 1.0 microg/kg
Number of subjects: 22
Study: 12870979

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants (Fuji II LC) placed on primary molars
Number of subjects: 65
Study: 10446101

Group type: EXPERIMENTAL
Intervention: Bethanechol (5 mg subcutaneously)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atropine (0.6 mg then 0.25 mg/hour intravenously)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 8709736

Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D-NMMA
Number of subjects: 10
Study: 1810282

Group type: EXPERIMENTAL
Intervention: Geriatric Assessment Unit (GAU)
Number of subjects: 267

Group type: COMPARATOR
Intervention: General Medical Units (GMUs)
Number of subjects: 267
Study: 6818867

Group type: EXPERIMENTAL
Intervention: Special splint technique
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional splint system
Number of subjects: 41
Study: 30910544

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome group
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Cumulative live birth rate
Number of subjects: 1508
Study: 28849329

Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 mcg BID (CIC)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 mcg BID (OIC)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Lubiprostone 8 mcg BID (IBS-C)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo (CIC)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo (OIC)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo (IBS-C)
Number of subjects: 316
Study: 26259896

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) delivered by a trained sexual health professional
Number of subjects: 207

Group type: COMPARATOR
Intervention: Usual Care (UC) - standard alcohol leaflet
Number of subjects: 207
Study: 25140033

Group type: EXPERIMENTAL
Intervention: Mouthpiece ventilation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nasal mask ventilation
Number of subjects: 50
Study: 21850553

Group type: EXPERIMENTAL
Intervention: Polyethylene mesh
Number of subjects: 35

Group type: COMPARATOR
Intervention: Polypropylene mesh
Number of subjects: 35
Study: 19292961

Group type: EXPERIMENTAL
Intervention: Conductive education combined with Frenkel training
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 115
Study: 17959973

Group type: EXPERIMENTAL
Intervention: Hypercapnia (ETco2 60 +/- 2 mm Hg)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Hypocapnia (ETco2 27 +/- 2 mm Hg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Normocapnia (ETco2 37 +/- 2 mm Hg)
Number of subjects: 180
Study: 15793171

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PC) program
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 198
Study: 11978650

Group type: COMPARATOR
Intervention: Systemic hyperinsulinemia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Locally administered insulin
Number of subjects: 18
Study: 9579501

Group type: EXPERIMENTAL
Intervention: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with abrupt discontinuation (group 1A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with abrupt discontinuation (group 2A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with descending concentrations (group 1B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with descending concentrations (group 2B)
Number of subjects: 0
Study: 7657917

Group type: EXPERIMENTAL
Intervention: In-home comprehensive geriatric assessment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Physician cooperation
Number of subjects: 81
Study: 2482536

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (Introna) 3 MU, 3 times weekly subcutaneously for 36 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (Introna)
Number of subjects: 33
Study: 320913

Group type: EXPERIMENTAL
Intervention: 5% solution of metaproterenol, 10 whiffs (1.5 mg) q.i.d.
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.5% isoproterenol solution
Number of subjects: 28
Study: 31289058

Group type: EXPERIMENTAL
Intervention: Early cholecystectomy (within 6 days after discharge)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Delayed (interval) cholecystectomy (between 45 and 60 days after discharge)
Number of subjects: 93
Study: 28566262

Group type: EXPERIMENTAL
Intervention: Tadalafil 20mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26024521

Group type: EXPERIMENTAL
Intervention: High-flux HD
Number of subjects: 127

Group type: COMPARATOR
Intervention: Low-flux HD
Number of subjects: 127

Group type: COMPARATOR
Intervention: Comparison between high-flux and low-flux HD
Number of subjects: 127
Study: 23705968

Group type: EXPERIMENTAL
Intervention: High intensity training (HIT) intervention - 3 weekly exercise sessions over 7 weeks, consisting of 4 to 6 repeats of maximal sprint running with 30 s recovery
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group - continued normal behavior
Number of subjects: 89
Study: 21726354

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment for 3 days
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment for 7 days
Number of subjects: 130
Study: 19696132

Group type: EXPERIMENTAL
Intervention: Exposure to suffering (experimental group)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Relaxing situations (control group)
Number of subjects: 89
Study: 16428214

Group type: EXPERIMENTAL
Intervention: Swanson implants
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sutter implants
Number of subjects: 53
Study: 14652361

Group type: EXPERIMENTAL
Intervention: Betaine 1.5 g/d
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Betaine 3 g/d
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Betaine 6 g/d
Number of subjects: 76
Study: 11247402

Group type: EXPERIMENTAL
Intervention: Holter ECG monitoring in patients with glucose metabolism disturbances
Number of subjects: 335

Group type: COMPARATOR
Intervention: Holter ECG monitoring in patients without glucose metabolism disturbances
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Holter ECG monitoring
Number of subjects: 335
Study: 8651147

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 0
Study: 1633794

Group type: EXPERIMENTAL
Intervention: Force-paced lifting (4 lifts/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Self-paced lifting (random order)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both pacing methods
Number of subjects: 10
Study: 6392161

Group type: EXPERIMENTAL
Intervention: Hexabrix (ratio 3)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Renografin‐76 (ratio 1.5)
Number of subjects: 50
Study: 31243928

Group type: EXPERIMENTAL
Intervention: PWC-positive group
Number of subjects: 110

Group type: COMPARATOR
Intervention: PWC-negative group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 110